CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives

Heart diseases remain the primary cause of human mortality in the world. Although conventional therapeutic opportunities fail to halt or recover cardiac fibrosis, the promising clinical results and therapeutic efficacy of engineered chimeric antigen receptor (CAR) T cell therapy show several advance...

Full description

Saved in:
Bibliographic Details
Published in:Cell biochemistry and function 2024-03, Vol.42 (2), p.e3955-n/a
Main Authors: Abdalla, Ahmed M. E., Miao, Yu, Ahmed, Ahmed I. M., Meng, Ning, Ouyang, Chenxi
Format: Article
Language:English
Subjects:
Antigens
cardiac fibrosis
Cardiovascular diseases
CAR‐T cell therapy
Cell culture
Cell therapy
Chimeric antigen receptors
fibroblast activation protein (FAP)
Fibrosis
Heart diseases
Humans
immune cells
Immune system
Immunotherapy, Adoptive - methods
Inflammation
Lymphocytes
Lymphocytes T
Medical treatment
Receptors
Receptors, Chimeric Antigen - therapeutic use
senescent cells
T-Lymphocytes
Therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heart diseases remain the primary cause of human mortality in the world. Although conventional therapeutic opportunities fail to halt or recover cardiac fibrosis, the promising clinical results and therapeutic efficacy of engineered chimeric antigen receptor (CAR) T cell therapy show several advancements. However, the current models of CAR‐T cells need further improvement since the T cells are associated with the triggering of excessive inflammatory cytokines that directly affect cardiac functions. Thus, the current study highlights the critical function of heart immune cells in tissue fibrosis and repair. The study also confirms CAR‐T cell as an emerging therapeutic for treating cardiac fibrosis, explores the current roadblocks to CAR‐T cell therapy, and considers future outlooks for research development. Significance statement The necessity and importance of chimeric antigen receptor (CAR) T cells and their therapeutic efficiency in treating diseases other than cancer, mainly cardiovascular diseases, have emerged in recent years. However, there is still room for advancement in the current models of CAR‐T cell therapy. This paper highlights the evolution and roadblocks of CAR‐T technology at different levels, from technical concerns to clinical outcomes, in an attempt to improve the therapeutic efficiency of CAR‐T cell therapy in this area.
ISSN:0263-6484
1099-0844
DOI:10.1002/cbf.3955